WebOct 18, 2024 · Brief Summary: Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological … WebApr 13, 2024 · About Tenalisib (RP6530): Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through …
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ ... - PubMed
WebFeb 1, 2024 · Tenalisib (RP6530), an isoflavone substituted adenine, is a highly specific and orally available PI3K δ/γ inhibitor. It has nanomolar inhibitory potency and several fold selectivity over α and β isoforms. WebMay 4, 2024 · About Tenalisib (RP6530): Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K δ/γ inhibitor with additional SIK3 activity, that is … canovas freeport illinois
Rhizen Pharmaceuticals S.A. Announces Publication of ... - BioSpace
WebApr 9, 2024 · “We are pleased to receive US FDA orphan-drug designations for the active moiety of Tenalisib (RP6530) for the treatment of peripheral and cutaneous T-cell Lymphoma (PTCL and CTCL),” said Swaroop Vakkalanka, PhD, Founder and President of Rhizen Pharmaceuticals SA, “and we look forward to advancing the drug into further … WebSep 24, 2024 · Tenalisib (RP6530) is a highly selective next generation orally active dual PI3K δ/γ inhibitor, which is in Phase 2 clinical development for hematological malignancies and solid tumors. Tenalisib has been granted US FDA Fast Track Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell … WebOct 13, 2024 · Rhizen Pharma commences dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer This multi-center, randomized phase II study is being conducted in eastern Europe and is designed to assess Tenalisib’s anti … canovee gaa facebook